265 related articles for article (PubMed ID: 9290695)
21. Active immunotherapy with allogeneic tumor cell vaccines: present status.
Chan AD; Morton DL
Semin Oncol; 1998 Dec; 25(6):611-22. PubMed ID: 9865676
[TBL] [Abstract][Full Text] [Related]
22. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma.
Wallack MK; Sivanandham M; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty LE; Richards JM; Bartolucci AA
Cancer; 1995 Jan; 75(1):34-42. PubMed ID: 7804974
[TBL] [Abstract][Full Text] [Related]
23. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
Speiser DE; Liénard D; Pittet MJ; Batard P; Rimoldi D; Guillaume P; Cerottini JC; Romero P
Eur J Immunol; 2002 Mar; 32(3):731-41. PubMed ID: 11870617
[TBL] [Abstract][Full Text] [Related]
24. Rational development of tumour antigen-specific immunization in melanoma.
Gajewski TF; Fallarino F
Ther Immunol; 1995 Aug; 2(4):211-25. PubMed ID: 9358613
[TBL] [Abstract][Full Text] [Related]
25. Emerging therapies for melanoma.
Katipamula R; Markovic SN
Expert Rev Anticancer Ther; 2008 Apr; 8(4):553-60. PubMed ID: 18402522
[TBL] [Abstract][Full Text] [Related]
26. Developing recombinant and synthetic vaccines for the treatment of melanoma.
Restifo NP; Rosenberg SA
Curr Opin Oncol; 1999 Jan; 11(1):50-7. PubMed ID: 9914879
[TBL] [Abstract][Full Text] [Related]
27. Current status of melanoma vaccines.
Kuhn CA; Hanke CW
Dermatol Surg; 1997 Aug; 23(8):649-54; discussion 654-5. PubMed ID: 9256911
[TBL] [Abstract][Full Text] [Related]
28. Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy.
Bredenbeck A; Losch FO; Sharav T; Eichler-Mertens M; Filter M; Givehchi A; Sterry W; Wrede P; Walden P
J Immunol; 2005 Jun; 174(11):6716-24. PubMed ID: 15905511
[TBL] [Abstract][Full Text] [Related]
29. Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells.
Livingston PO; Watanabe T; Shiku H; Houghton AN; Albino A; Takahashi T; Resnick LA; Michitsch R; Pinsky CM; Oettgen HF; Old LJ
Int J Cancer; 1982 Oct; 30(4):413-22. PubMed ID: 7141736
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy, including gene therapy, for metastatic melanoma.
O'Rourke MG; Schmidt CW; O'Rourke TR; Ellem KA
Aust N Z J Surg; 1997 Dec; 67(12):834-41. PubMed ID: 9451336
[TBL] [Abstract][Full Text] [Related]
31. Melanoma vaccines: mixed past, promising future.
Ozao-Choy J; Lee DJ; Faries MB
Surg Clin North Am; 2014 Oct; 94(5):1017-30, viii. PubMed ID: 25245965
[TBL] [Abstract][Full Text] [Related]
32. Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects.
Minev BR; Guo F; Gueorguieva I; Kaiser HE
In Vivo; 2002; 16(6):405-15. PubMed ID: 12494883
[TBL] [Abstract][Full Text] [Related]
33. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.
Schadendorf D; Paschen A; Sun Y
Immunol Lett; 2000 Sep; 74(1):67-74. PubMed ID: 10996630
[TBL] [Abstract][Full Text] [Related]
34. Vaccine therapy in the treatment of melanoma.
Maguire HC
Int J Dermatol; 1993 Apr; 32(4):259-60. PubMed ID: 8486456
[No Abstract] [Full Text] [Related]
35. Immunotherapy for malignant melanoma: a review and update.
McGee JM
Semin Surg Oncol; 1991; 7(4):217-20. PubMed ID: 1925253
[TBL] [Abstract][Full Text] [Related]
36. Special report: vaccines for the treatment of malignant melanoma.
Tecnologica MAP Suppl; 2001 Apr; ():19-20. PubMed ID: 11718143
[TBL] [Abstract][Full Text] [Related]
37. Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies.
Wages NA; Slingluff CL; Petroni GR
Ann Oncol; 2017 Apr; 28(4):696-701. PubMed ID: 28011450
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic vaccines for melanoma: progress and problems.
Jones VE; Mitchell MS
Trends Biotechnol; 1996 Sep; 14(9):349-55. PubMed ID: 8818289
[TBL] [Abstract][Full Text] [Related]
39. [Development in the immunotherapy of malignant melanoma].
Tritsch H
Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
Sosman JA; Unger JM; Liu PY; Flaherty LE; Park MS; Kempf RA; Thompson JA; Terasaki PI; Sondak VK;
J Clin Oncol; 2002 Apr; 20(8):2067-75. PubMed ID: 11956267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
